Corcept Therapeutics Inc
A California drugmaker that tames the stress hormone cortisol, which the body pumps out in excess in some illnesses. Its best-known medicine, Korlym, treats Cushing's syndrome, a condition where too much cortisol causes high blood sugar and other troubles. Founded in 1998 by two Stanford psychiatrists, the company got its name from a mashup of "cortisol" and "concept." Its founding idea grew out of a Stanford researcher's hunch that the abortion pill mifepristone could also block cortisol's effects — a hunch that later became its flagship drug.
Bought 3.20M · Sold 2.60M
Granted 146.1K · Bought 349.7K
Granted 349.4K · Bought 4.64M
Bought 5.01M
Bought 3.24M
Bought 3.08M
Granted 4.60M · Sold 2.06M
Bought 3.10M
Granted 349.4K · Bought 7.84M · Sold 6.72M
Bought 349.7K
Bought 2.61M
Granted 410.0K · Bought 6.20M · Sold 434.4K
Granted 104.8K
Bought 1.06M
Bought 878.7K
Bought 878.7K
Granted 217.5K · Bought 2.85M · Sold 92.3K
Bought 2.53M
Granted 1.50M · Bought 728.6K · Sold 448.4K
Bought 50.0K
Granted 536.0K · Bought 981.1K · Sold 269.8K
Granted 706.2K · Sold 120.8K
Bought 2.62M
Granted 650.0K · Sold 20.5K
Bought 2.61M
Granted 209.7K · Bought 5.41M · Sold 11.55M
Bought 2.63M
Granted 1.11M · Sold 969.2K
Bought 317.9K · Sold 140.0K
Granted 1.22M · Bought 5.6K · Sold 520.5K
Granted 209.7K · Bought 5.41M · Sold 11.80M
Bought 2.58M
Bought 57.9K
Granted 99.3K · Sold 80.0K
Granted 50.0K
Bought 1.38M
Granted 430.2K · Sold 429.0K
Bought 501.9K
Bought 10.0K
Bought 10.0K
Granted 471.0K · Sold 461.4K
Granted 117.7K · Sold 113.0K
Granted 265.0K · Sold 442.6K
Granted 96.0K · Sold 96.0K
Granted 11.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Longitude Venture Partners L.P. +3 co-filers10% owner · 44 transactions | — | 24.91Mas of Nov 2016 | — | 3.20M | 2.60M |
| Tammenoms Bakker Juliet10% owner · 2 transactions | — | 11.09Mas of Dec 2016 | — | — | — |
| Penhoet Edward10% owner · 8 transactions | — | 10.99Mas of Apr 2010 | 146.1K | 349.7K | — |
| Longitude Venture Partners LP +3 co-filers10% owner, Director, 10% owner · 2 transactions | — | 8.52Mas of Feb 2009 | 349.4K | 4.64M | — |
| Marduel AlixDirector, 10% owner · 5 transactions | — | 7.52Mas of Mar 2008 | — | 5.01M | — |
| Coxe TenchFormer 10% Owner · 23 transactions | — | 6.89Mas of Feb 2013 | — | 3.24M | — |
| Anderson David LFormer 10% Owner · 26 transactions | — | 6.42Mas of Feb 2013 | — | 3.08M | — |
| Belanoff Joseph KChief Executive Officer, Director · 131 transactions | — | 6.36M | 4.60M | — | 2.06M |
| Younger William H Jr10% owner · 35 transactions | — | 6.33Mas of Feb 2013 | — | 3.10M | — |
| Enright Patrick GDirector · 61 transactions | — | 6.11Mas of Mar 2017 | 349.4K | 7.84M | 6.72M |
| Alta Biopharma Management II LLC +5 co-filers10% owner · 2 transactions | — | 5.66Mas of Oct 2009 | — | 349.7K | — |
| Gaither James C10% owner · 25 transactions | — | 5.56Mas of Feb 2013 | — | 2.61M | — |
| Baker G Leonard JrDirector · 146 transactions | — | 5.53M | 410.0K | 6.20M | 434.4K |
| Anderson David L +9 co-filers10% owner, Director, 10% owner · 1 transaction | — | 5.32Mas of Mar 2012 | — | — | — |
| Sutter Hill Ventures +1 co-filer10% owner · 1 transaction | — | 5.32Mas of Mar 2012 | — | — | — |
| Alta Biopharma Management II LLC +6 co-filers10% owner · 2 transactions | — | 5.31Mas of Nov 2008 | 104.8K | — | — |
| Alta Biopharma Partners II LP +5 co-filers10% owner · 2 transactions | — | 5.04Mas of Mar 2008 | — | 1.06M | — |
| Anderson David L +9 co-filers10% owner, Director, 10% owner · 3 transactions | — | 5.04Mas of Oct 2011 | — | 878.7K | — |
| Bird Jeffrey W +2 co-filers10% owner · 3 transactions | — | 5.04Mas of Oct 2011 | — | 878.7K | — |
| Cook Joseph C JrDirector · 37 transactions | — | 4.95Mas of Mar 2015 | 217.5K | 2.85M | 92.3K |
| Sutter Hill Ventures10% owner · 7 transactions | — | 4.34Mas of Feb 2009 | — | 2.53M | — |
| Wilson James NDirector · 118 transactions | — | 2.82M | 1.50M | 728.6K | 448.4K |
| Schatzberg Alan FDirector, 10% owner · 1 transaction | — | 2.74Mas of Apr 2007 | — | 50.0K | — |
| Mahoney David LDirector · 63 transactions | — | 2.55M | 536.0K | 981.1K | 269.8K |
| Singer David BDirector · 3 transactions | — | 792.0Kas of Feb 2008 | — | — | — |
| Lo StevenSVP Oncology · 11 transactions | — | 433.3Kas of Nov 2015 | 706.2K | — | 120.8K |
| White James N10% owner · 19 transactions | — | 266.8Kas of Apr 2012 | — | 2.62M | — |
| Hunt HazelChief Scientific Officer · 19 transactions | — | 255.4K | 650.0K | — | 20.5K |
| Bird Jeffrey W10% owner · 20 transactions | — | 242.2Kas of Mar 2012 | — | 2.61M | — |
| Paperboy Ventures, LLCDirector · 56 transactions | — | 209.7Kas of May 2009 | 209.7K | 5.41M | 11.55M |
| Sands Gregory P10% owner · 18 transactions | — | 193.2Kas of Oct 2011 | — | 2.63M | — |
| Maduck SeanSee Remarks · 191 transactions | — | 137.7K | 1.11M | — | 969.2K |
| Bradbury DanielDirector · 19 transactions | — | 130.6Kas of Feb 2019 | — | 317.9K | 140.0K |
| Robb Gary CharlesChief Business Officer · 179 transactions | — | 125.0K | 1.22M | 5.6K | 520.5K |
| Andersson AllenDirector · 60 transactions | — | 97.1Kas of May 2009 | 209.7K | 5.41M | 11.80M |
| Sweet David E10% owner · 21 transactions | — | 97.0Kas of Apr 2012 | — | 2.58M | — |
| Harper James ADirector · 4 transactions | — | 67.4Kas of Jul 2010 | — | 57.9K | — |
| Mokari AtabakChief Financial Officer · 47 transactions | — | 56.1K | 99.3K | — | 80.0K |
| LeDoux Anne MVP & Controller · 2 transactions | — | 50.0Kas of Sep 2015 | 50.0K | — | — |
| Sheehan Andrew T10% owner · 10 transactions | — | 40.1Kas of Mar 2012 | — | 1.38M | — |
| Guyer WilliamChief Development Officer · 89 transactions | — | 29.5K | 430.2K | — | 429.0K |
| Speiser Michael L10% owner · 4 transactions | — | 13.4Kas of Mar 2012 | — | 501.9K | — |
| Gala Renee DDirector · 2 transactions | — | 10.0Kas of Mar 2018 | — | 10.0K | — |
| Turner Joseph LDirector · 2 transactions | — | 10.0Kas of Mar 2013 | — | 10.0K | — |
| Lyon Joseph DouglasSee Remarks · 128 transactions | — | 7.0K | 471.0K | — | 461.4K |
| Swisher Daniel N JRDirector · 73 transactions | — | 2.2K | 117.7K | — | 113.0K |
| Roe Robert LPresident and Secretary · 66 transactions | — | 0as of Aug 2012 | 265.0K | — | 442.6K |
| Fishman Robert SChief Medical Officer · 24 transactions | — | 0as of Nov 2018 | 96.0K | — | 96.0K |
| Cannon GillianDirector · 3 transactions | — | 0 | 11.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +33.74M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.